CAMBRIDGE, Mass.--(BUSINESS WIRE)--AILERON Therapeutics, a biopharmaceutical company applying its proprietary Stapled Peptide technology to the development of breakthrough biologics for the treatment of cancer and other diseases, today announced that Tomi K. Sawyer, Ph.D., has joined the company as Chief Scientific Officer. Dr. Sawyer was most recently the Head of Chemistry for the Pfizer Research Technology Center in Cambridge, Mass. He will lead AILERON’s internal and external drug discovery programs and will oversee the immediate expansion of its R&D capabilities.
